Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.
Male or female aged 18 years or more
Histologically confirmed breast cancer at any stage
Requiring surgery or tumor biopsy as standard of care
Any or no systemic treatment
Opposed to biospecimen collection
This is a cohort study conducted in breast cancer patients requiring a surgery or a tumor biopsy as part of their care.
Cohort
Prospective
Not listed
Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers
Measurement of the phagocytic capacity
Antitumor activity of the CAR-macrophages compared to non-modified macrophages
Measurement of the phagocytic capacity
Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients
Measurement of the phagocytic capacity
Click on the lead sponsor to view all of their trials.
Centre Oscar Lambret
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
